Gary S. Gordon, Everett E, Vokes, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD
Source: Oncology, 13:1075-1088, August 1999
This comprehensive review of the management of locally advanced unresectable non-small-cell lung cancer (NSCLC) summarizes major landmark studies that have led to the current standard of care. In addition, more recent ongoing trials using altered radiation schedules and new chemotherapeutic agents are discussed.
Based on the encouraging results from trials of accelerated hyperfractionated radiation therapy in NSCLC, the Eastern Cooperative Oncology Group (ECOG) has initiated a randomized trial of induction taxol and carboplatin chemotherapy followed by standard radiation Vs the same induction chemotherapy followed by hyperfractionated accelerated radiation therapy (HART).
Some novel anticancer agents with unique mechanisms of action have been tested in phase I/II trials and shown encouraging results. We expect to see more trials incorporating of these new agents into the treatment of NSCLC in the future.